Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.

Sabri M, Ai J, Macdonald RL.

Stroke. 2011 May;42(5):1454-60. doi: 10.1161/STROKEAHA.110.604728. Epub 2011 Mar 31.

2.

Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.

Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, Lakovic K, Wan H, Macdonald RL.

Brain Res. 2011 May 25;1392:132-9. doi: 10.1016/j.brainres.2011.03.068. Epub 2011 Apr 3.

PMID:
21466789
3.

Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.

Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, Vajkoczy P.

Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. Epub 2007 Aug 13.

PMID:
17700991
4.

Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.

Vergouwen MD.

Stroke. 2009 Dec;40(12):e714; author reply e715-6. doi: 10.1161/STROKEAHA.109.565887. Epub 2009 Oct 29. No abstract available.

5.

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A; CONSCIOUS-1 Investigators.

Stroke. 2008 Nov;39(11):3015-21. doi: 10.1161/STROKEAHA.108.519942. Epub 2008 Aug 7.

6.

Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.

Macdonald RL.

Expert Opin Investig Drugs. 2008 Nov;17(11):1761-7. doi: 10.1517/13543784.17.11.1761 .

PMID:
18922111
7.

The effect of endothelin receptor antagonists on vasospasm following aneurysmal subarachnoid hemorrhage.

Komotar RJ, Starke RM, Connolly ES.

Neurosurgery. 2011 Dec;69(6):N13-4. doi: 10.1227/01.neu.0000407918.14115.e5. No abstract available.

PMID:
22067343
8.

Clazosentan for patients with subarachnoid haemorrhage: lessons learned.

Wong GK, Poon WS.

Lancet Neurol. 2011 Oct;10(10):871; author reply 871-2. doi: 10.1016/S1474-4422(11)70189-2. No abstract available.

PMID:
21939894
9.

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Lancet Neurol. 2011 Jul;10(7):618-25. doi: 10.1016/S1474-4422(11)70108-9. Epub 2011 Jun 2.

PMID:
21640651
10.

Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.

Vergouwen MD, Algra A, Rinkel GJ.

Stroke. 2012 Oct;43(10):2671-6. Epub 2012 Aug 7. Review. Erratum in: Stroke. 2013 Jun;44(6):e72.

11.
12.

Clazosentan (Actelion).

Uhlmann D.

Curr Opin Investig Drugs. 2006 Mar;7(3):272-81.

PMID:
16555688
13.

Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.

Shen J, Pan JW, Fan ZX, Xiong XX, Zhan RY.

J Neurosurg. 2013 Jul;119(1):180-9. doi: 10.3171/2013.3.JNS121436. Epub 2013 May 3. Review.

PMID:
23641823
14.

Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.

Beck J, Raabe A.

Acta Neurochir Suppl. 2011;110(Pt 2):147-50. doi: 10.1007/978-3-7091-0356-2_26.

PMID:
21125461
15.

Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.

Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ.

PLoS One. 2012;7(10):e47778. doi: 10.1371/journal.pone.0047778. Epub 2012 Oct 17.

16.

Is vasospasm actually bad for you?

Crowley RW, Macdonald RL.

World Neurosurg. 2011 Jul-Aug;76(1-2):6. doi: 10.1016/j.wneu.2011.05.040. No abstract available.

PMID:
21839927
18.

Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study.

Pearl JD, Macdonald RL.

Acta Neurochir Suppl. 2008;105:207-10. Review.

PMID:
19066110
19.

Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Acta Neurochir Suppl. 2013;115:27-31. doi: 10.1007/978-3-7091-1192-5_7.

PMID:
22890639
20.

Impact of systemic inflammatory response syndrome on vasospasm, cerebral infarction, and outcome after subarachnoid hemorrhage: exploratory analysis of CONSCIOUS-1 database.

Tam AK, Ilodigwe D, Mocco J, Mayer S, Kassell N, Ruefenacht D, Schmiedek P, Weidauer S, Pasqualin A, Macdonald RL.

Neurocrit Care. 2010 Oct;13(2):182-9. doi: 10.1007/s12028-010-9402-x.

PMID:
20593247
Items per page

Supplemental Content

Write to the Help Desk